Lundbeck Q3 2019 Financial Results

Financial terms and territory structure of the Otsuka alliance entered in November 2011 Milestone payments Payment to: Otsuka Abilify Maintena Lundbeck's share of revenue and costs Lundbeck⭑ Otsuka Lundbeck⭑ Abilify Maintena Rexulti Selincro 62 Rexulti Selincro Development milestones/upfront USD 200m USD 600m³) EUR 105m* USA 20% 45% Approval milestones USD 275m1) USD 300m²) Un- disclosed EU-5, Nordic and 50% 50% Canada Sales milestones Up to USD 425m depending on sales development Un- disclosed Other Lundbeck territories 65%** 65%** Un- disclosed * Includes sales milestones 1) USD 100m upon US approval, USD 75m upon EU approval in schizophrenia, and USD 50m US and EU for a second indication. 2) USD 100m (US) and USD 50m (EU) for each of the two first indications 3) Development milestones of up to USD 600m after which shared development costs between parties. 4) USD 125m, USD 25m and USD 50m for first indication in the US, EU and Japan respectively. Second indication gives USD 50m, USD 25m and USD 25m, respectively. ** All regions except Asia, Turkey and Egypt *** All regions except Thailand and Vietnam * Selincro for Japan added to the alliance in October 2013 Lundbeck

View entire presentation